Randomized Safety Study of CVT-301 Compared to an Observational Control Group
NCT02352363
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
408
Enrollment
INDUSTRY
Sponsor class
Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG:
CVT-301
OTHER:
Observational cohort
Sponsor
Acorda Therapeutics